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In this study we report for the first time the functional
properties of human myotubes isolated from patients
harboring the native RYR1 I4898T and R4893W muta-
tions linked to central core disease. We examined two
aspects of myotube physiology, namely excitation-con-
traction and excitation-secretion coupling. Our results
show that upon activation of the ryanodine receptor
(RYR), myotubes release interleukin-6 (IL-6); this was
dependent on de novo protein synthesis and could be
blocked by dantrolene and cyclosporine. Myotubes from
the two patients affected by central core disease showed
a 4-fold increase in the release of the inflammatory cy-
tokine IL-6, compared with cells derived from control or
malignant hyperthermia susceptible individuals. All
tested myotubes released calcium from intracellular
stores upon stimulation via surface membrane depolar-
ization or direct RYR activation by 4-chloro-m-cresol.
The functional impact on calcium release of RYR1 mu-
tations linked to central core disease or malignant hy-
perthermia is different: human myotubes carrying the
malignant hyperthermia-linked RYR1 mutation V2168M
had a shift in their sensitivity to the RYR agonist
4-chloro-m-cresol to lower concentrations, whereas hu-
man myotubes harboring C-terminal mutations linked
to central core disease exhibited reduced [Ca2]i in-
crease in response to 4-chloro-m-cresol, caffeine, and
KCl. Taken together, these results suggest that abnor-
mal release of calcium via mutated RYR enhances the
production of the inflammatory cytokine IL-6, which
may in turn affect signaling pathways responsible for
the trophic status of muscle fibers.
Central core disease (CCD)1 is a congenital myopathy of
autosomal dominant inheritance. Affected individuals often
present with infantile hypotonia (floppy infant syndrome),
weakness, hip dislocation, and a delay in achieving motor mile-
stones. Later in life, the predominant symptom is a generalized
muscle weakness affecting the proximal muscle groups more
than the distal ones. The clinical severity is highly variable, but
disease course is usually slow or nonprogressive (1–4). On the
basis of clinical findings alone the diagnosis is difficult, and a
histological examination of muscle tissue is essential. Typi-
cally, type I fibers are predominant and contain well demar-
cated and centrally located cores, which lack mitochondria and
do not stain with histochemical dyes for oxidative enzymes. In
longitudinal sections the core area is extensive and covers a
considerable length of the fiber (4–6).
From a molecular point of view CCD is closely associated
with malignant hyperthermia (MH), because both disorders
are caused by mutations in the ryanodine receptor (RYR1), the
calcium release channel of the sarcoplasmic reticulum. MH is a
pharmacogenetic disease triggered by volatile anesthetics and
the depolarizing muscle relaxant suxamethonium in predis-
posed (MH-susceptible (MHS)) individuals (7, 8). The clinical
signs of an impending MH reaction are due to a hypermetabolic
state and include muscle rigidity, metabolic acidosis, rhab-
domyolysis, tachycardia, and/or an increase in body tempera-
ture. Histological examination of muscle fibers from MHS in-
dividuals does not reveal alterations of the status of the muscle.
To date more than 40 mutations have been identified in the
ryanodine receptor gene (RYR1, human chromosome 19q13.1)
and are associated with MH and/or CCD (for review see Refs.
9–11). The RYR1 gene is comprised of 106 exons that code for
one of the largest known proteins (5038 amino acids) (12, 13).
The first 4000 amino acids are predicted to form the hydro-
philic cytoplasmic domain, whereas the last 1000 amino acids
form the hydrophobic membrane-spanning pore (14–16). The
majority of RYR1 mutations giving rise to the MHS phenotype
appear to be clustered in the hydrophilic domain, whereas most
mutations linked to CCD have been found in hydrophobic pore-
forming domain 3 (17–20).
To understand the molecular mechanism underlying MH
and CCD, it is essential to evaluate the impact of mutations on
the functional properties of the RYR calcium channels and on
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excitation-contraction coupling. As far as MH-linked RYR1
mutations are concerned, in most cases they cause an increased
sensitivity of the RYR to pharmacological agonists such as
caffeine, 4-chloro-m-cresol, and halothane (21–25). On the
other hand, mutations causing CCD have been shown to lead to
leaky calcium channels that can cause depletion of intracellu-
lar calcium pools (17, 20), or to uncoupled RYR calcium chan-
nels in which depolarization of the dihydropyridine receptor
does not lead to opening of the RYR calcium channel (26, 27).
Thus, the impact of most disease-causing RYR1 mutations will
necessarily affect calcium homeostasis of the muscle cell. To
date, however, only few downstream effects of the altered in-
tracellular calcium homeostasis have been investigated.
Calcium-dependent pathways regulate many aspects of mus-
cle physiology, including growth and regeneration (28, 29).
Increases in [Ca2]i have been shown to activate transcription
of the pro-inflammatory regulators nuclear factor B (NF-B),
c-Jun N-terminal kinase (JNK), and nuclear factor of activated
T cells (NF-AT) via activation of the calcium sensitive-phos-
phatase calcineurin (30). Skeletal muscle cells are capable of
producing and responding to several cytokines such as IL-4,
IL-6, IL-15, and tumor necrosis factor (31–34). Although the
fine mechanism controlling cytokine release is not fully under-
stood, muscle exercise has been shown to increase the plasma
concentration of IL-6, which in turn has been proposed to exert
a role on the maintenance of glucose homeostasis, its full phys-
iological role, however, has yet to be established (for review see
Ref. 32). When released in large quantities, IL-6 and IL-1 cause
fever; i.e. they constitute an endogenous pyrogen and can in-
duce the synthesis of acute phase plasma proteins and initiate
metabolic wasting (35). Because the mechanism underlying
CCD appears to be controversial, in the present report we
examined how two endogenously expressed CCD-linked RYR1
mutations affect [Ca2]i homeostasis and cytokine release from
cultured human myotubes and compared their properties to
those of myotubes from control individuals or MHS individuals
carrying a RYR1 mutation in a different domain of the calcium
release channel.
EXPERIMENTAL PROCEDURES
Materials—Dulbecco’s modified Eagle’s medium containing 4.5
mg/ml glucose, penicillin G, streptomycin, were all purchased from
Invitrogen. Insulin was purchased from Eli Lilly and Co. (Indianapolis,
IN). Cell culture plastic ware was from BD Biosciences. Glutamine,
HEPES, bovine serum albumin, epidermal growth factor, cyclohexi-
mide, anti--actinin, anti-goat-FITC, anti-mouse-cy3, creatine, and
dantrolene were from Sigma. Fura-2/AM and cyclosporine A were from
Calbiochem. The calcium calibration kit was from Molecular Probes,
Inc. A goat anti-1.1 subunit of the skeletal muscle dihydropyridine
receptor polyclonal antibodies was from Santa Cruz Biotechnology Inc.
PeliKine-compact human IL-1 and IL-6 ELISA kits were from CLB,
Amsterdam, The Netherlands. Mouse monoclonal antibody anti-IL-6R
(CD130) was from BIOSOURCE International (Camarillo, CA). All
other chemicals were reagent or highest available grade.
Patients, Identification of RYR1 Mutations, and Human Skeletal
Muscle Cell Culture—Primary human muscle cell cultures were estab-
lished after obtaining informed consent from muscle biopsies of patients
undergoing the in vitro contracture test for the diagnosis of MH sus-
ceptibility, in 10 control patients from 3 different families, 9 patients
with a positive family history for MH in which the V2168M mutation in
the RYR1 gene was identified (from 5 different families), and from 2
patients affected by CCD. In these patients, exons 98–103 of the RYR1
gene, the major mutation hot spot, were screened for mutations by
single strand conformation analysis and direct sequencing as described
previously (20).
Human skeletal muscle cell cultures were established as previously
described (22). To differentiate cells into myotubes, the medium was
switched to Dulbecco’s modified Eagle’s medium plus 4.5 mg/ml glucose,
0.5% bovine serum albumin, 10 ng/ml epidermal growth factor, 0.15
mg/ml creatine, 5 ng/ml insulin, 200 mM glutamine, 600 ng/ml penicillin
G and streptomycin, and 7 mM HEPES, pH 7.4 (36).
Intracellular [Ca2] Measurements—Cells were transferred onto
glass coverslips (5 cm in diameter) and allowed to proliferate in growth
medium until visible groups of 10 cells were formed. The medium was
then switched to differentiation medium, and [Ca2] measurements
were performed 7–10 days later. The free cytosolic [Ca2] was deter-
mined using the fluorescent Ca2 indicator Fura-2 as described (22).
Coverslips were mounted onto a 37 °C thermostatted chamber, which
was continuously perfused with Krebs Ringer medium; individual cells
were stimulated with a 12-way 100-mm diameter quartz micromanifold
computer-controlled microperfuser (ALA Scientific) as previously de-
scribed (37). On-line (340 nm, 380 nm, and ratio) measurements were
recorded using a fluorescent Axiovert S100 TV inverted microscope
(Carl Zeiss GmbH, Jena, Germany) equipped with a 20 water-immer-
sion FLUAR objective (0.17 numerical aperture) with filters (BP 340/
380, FT 425, and BP 500/530) and attached to a Hamamatsu multifor-
mat charge-coupled device camera. The cells were analyzed using an
Openlab imaging system, and the average pixel value for each cell was
measured at excitation wavelengths of 340 and 380 nm. Ca2 calibra-
tion was performed following the instructions provided with the calcium
calibration kit.
Release of Cytokines—Human skeletal muscle cells were placed in
the wells of a 24-microtiter plate and allowed to grow until visible
aggregates of 10 cells were seen. The medium was then switched to
differentiation medium for 7–10 days. On the day of the experiment
the medium was changed, and cells were stimulated at 37 °C under the
specified conditions. The amount of IL-1 or IL-6 released into the
supernatant was determined by using the CLB PeliKine Compact in-
direct ELISA kit following the manufacturer’s instructions. All tests
were performed in duplicate.
Immunofluorescence—Undifferentiated myoblasts, growing in
growth medium or myotubes 7–10 days after being grown in differen-
tiation medium, were rinsed, fixed in ice-cold methanol:acetone (1:1) for
20 min, and processed as previously described (22). Fluorescence was
detected using a fluorescence Axiovert S100 TV inverted microscope
(Carl Zeiss GmbH, Jena, Germany) equipped with a 20 FLUAR ob-
jective and Zeiss filter sets (BP 475/40, FT 500, and BP 530/50; and BP
546, FT 560, and BP 575–640) for detection of FITC and Cy3 fluores-
cence, respectively.
Statistical Analysis—Statistical analysis was performed using the
Student’s t test for paired samples when there were two groups and
ANOVA for more than two groups. Origin computer program (Microcal
Software, Inc., Northampton, MA) was used for statistical analysis and
curve generation.
RESULTS
RYR1 Mutation Analysis—RYR1 mutations of the nine MH
patients have been identified and described earlier (38). In the
two patients diagnosed clinically and histologically as having
CCD we screened exons 98–103 of the RYR1 gene by SCCA. We
concentrated on this region, because it is part of the highly
conserved hydrophobic C-terminal domain of the RYR1 protein
and has been found to be a hot spot for CCD-linked mutations
(19, 20). Aberrant bands were identified, and direct DNA se-
quencing confirmed the presence of mutations I4898T in pa-
tient CCD1 and of R4893W in patient CCD2.
Differentiated Cultured Human Skeletal Muscle Cells Ex-
press Proteins Characteristic of Differentiated Skeletal Mus-
cle—To demonstrate that under our experimental culture con-
ditions human primary muscle cells differentiate sufficiently,
we performed immunofluorescence studies. Fig. 1 shows the
appearance of human myoblasts cultured under growth condi-
tions (Fig. 1, A–E) or myotubes after 7–10 days of culture in
differentiation medium (Fig. 1, F–J). The expression of cy-
toskeletal proteins specific for skeletal muscle was demon-
strated using an anti--sarcomeric actinin mouse monoclonal
antibody. This protein is expressed only in striated muscle cells
and is used to identify cells or tissues of striated muscle lineage
(39). Fig. 1 (B and G) shows the fluorescence pattern of cultured
human muscle cells: undifferentiated myoblasts are immunon-
egative, while differentiated myotubes exhibit a fluorescent
pattern that is compatible with that of a cytoskeletal protein.
Fig. 1 (C–I) shows the immunofluorescent patterns obtained
using anti-RYR1 (Fig. 1, C and H) and anti-1.1 dihydropyri-
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dine antibodies (Fig. 1, D and I), confirming that myotubes
express the two main protein components of skeletal muscle
excitation-contraction coupling (40–42). We also verified
whether cultured muscle cells express the IL-6 receptor, be-
cause IL-6 is released in large quantities during intense muscle
activity (32). Of interest, immature myoblasts did not express
the IL-6 receptor (Fig. 1E), whereas differentiated cells were
immunopositive (Fig. 1J).
Activation of the RYR Leads to IL-6 Release from Cultured
Human Myotubes—We next carried out experiments aimed at
determining whether activation of the RYR leads to IL-6 re-
lease from cultured human myotubes. On the day of the exper-
iment, differentiation medium was replaced with fresh differ-
entiation medium containing no agonist or 4-chloro-m-cresol or
caffeine. Cells from three control individuals were incubated at
37 °C for different time periods, and the amount of IL-6 re-
leased into the supernatant was determined by ELISA. Fig. 2
shows the time course of IL-6 release after treatment with 600
M 4-chloro-m-cresol (Fig. 2A) and 10 mM caffeine (Fig. 2B).
Maximal release was obtained 4–6 h after addition of either
agonist, indicating that activation of the RYR most likely does
not result in the release of pre-formed cytokine but stimulates
activation of transcription and protein synthesis. The total
amount of IL-6 released into the supernatant after 6 h of
FIG. 1. Photomicrograph of cultured human myoblasts and
myotubes. A–E, myoblasts cultured in growth medium. F–J myotubes
cultured for 7–10 days in differentiation medium. A and F, phase-
contrast micrograph. Note the presence of 5 nuclei in the uppermost
cell of panel F. B–J, indirect immunofluorescent staining for sarcomeric
-actinin (B and G), skeletal muscle RYR (C and H), 1.1 subunit of the
dihydropyridine receptor (D and I), and IL-6 receptor (E and J). 20
Zeiss FLUAR objective; magnification, 500).
FIG. 2. Time course of IL-6 release by human myotubes from
normal individuals, induced by pharmacological activation of
the ryanodine receptor. A and B, cells were incubated in differenti-
ation medium plus 600 M 4-chloro-m-cresol (A) or 10 mM caffeine (B) at
37 °C for the indicated times. The amount of IL-6 released into the
supernatant was determined by ELISA. The results are expressed as
percent increase in IL-6 released; the maximal amount of IL-6 released
by the RYR1 agonists was considered 100%. The results are the mean
S.E. of three experiments carried out in duplicate on cultures estab-
lished from three different control individuals. The mean maximal IL-6
released by 600 M 4-chloro-m-cresol and 10 mM caffeine was 5.0  0.7
and 7.5  1.2 ng/106 cells, respectively. C, IL-6 release induced by a 5-h
incubation with 600 M 4-chloro-m-cresol is significantly reduced in the
presence of dantrolene (dantro, 20 M), cyclosporine A (CsA, 100 nM),
and cycloheximide (CHX, 3 g/ml). Bckg represents the background
IL-6 release of myotubes incubated for 5 h in the absence of added
agonist. Results represent the mean ( S.E.) of at least four separate
experiments carried out in duplicate (Student’s t test; *, p  0.00001).
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incubation of muscle cells from control individuals with 600 M
4-chloro-m-cresol and 10 mM caffeine was 5.0  0.7 and 7.5 
1.2 ng/106 cells, respectively.
To verify that this IL-6 release was (i) dependent on protein
synthesis and (ii) dependent on activation of the RYR1, we
performed experiments on cells stimulated with 600 M
4-chloro-m-cresol, which had been pre-treated with cyclohexi-
mide to inhibit protein synthesis (3 g/ml, 30 min) (43), dan-
trolene (20 M, 30 min) (44) to prevent activation of RYR, or
cyclosporine (100 nM, 30 min) (45) to block calcium-dependent
calcineurin activation of the transcription factor NF-AT. Pre-
treatment with any of the three compounds resulted in a sig-
nificant inhibition (50%, p  0.00001, Student’s t test) of
4-chloro-m-cresol-activated IL-6 release (Fig. 2C). Background
IL-6 release after 5 h of incubation of the myotubes at 37 °C in
the absence of any RYR agonist was 31.3%  3.2 of the maxi-
mal release (mean  S.E.; n  6). Contrary to what was
observed in lymphocytes (46), treatment of human myotubes
with 4-chloro-m-cresol or caffeine did not result in the release
of significant amounts of IL-1 (50 pg/106 cells).
We next determined the dose-response curves of 4-chloro-m-
cresol-induced and caffeine-induced IL-6 release from human
myotubes obtained from control individuals. Fig. 3 shows that
treatment of cells with either agonist resulted in the significant
release of IL-6 (p  0.0018; ANOVA). The release could be
blocked by pre-treatment with 20 M dantrolene. In cells from
control individuals, the maximal release was obtained at a
concentration of 300 M 4-chloro-m-cresol and 10 mM caffeine:
the mean ( S.E.) IL-6 released was 6.0  1.1 ng/106 cells and
7.1  1.1 ng/106 cells, respectively (Fig. 3, A and E). These
results represent the mean of eight different experiments car-
ried out on muscle cells from at least four different individuals.
The amounts of IL-6 released by 10 mM caffeine or 300 M
4-chloro-m-cresol were not significantly different (p  0.497).
Of interest, treatment with either agonist resulted in a larger
amount (1.4-fold) of cytokine release compared with that ob-
tained by treating the cells with 1 M ionomycin (mean  S.E.;
IL-6 released was 5.3  0.8 ng/106 cells; not shown).
When the same experiment was performed on cells from
MHS individuals carrying the RYR1 V2168M mutation, addi-
tion of 4-chloro-m-cresol and caffeine resulted in the significant
release of IL-6 (p  0.0001; ANOVA). Maximal release was
obtained at a concentration of 75 M 4-chloro-m-cresol and 10
mM caffeine: the mean ( S.E.) IL-6 released was 7.2  1.3
ng/106 cells and 8.4  1.3 ng/106 cells, respectively (Fig. 3, B
and F). Pre-treatment of the cells with 20 M dantrolene inhib-
ited IL-6 release, whereas treatment with 1 M ionomycin
FIG. 3. Dose-dependent 4-chloro-m-cresol and caffeine-induced IL-6 release from human myotubes from control individuals and
patients bearing MH and CCD-linked RYR1 mutations. Cells were incubated for 5 h in differentiation medium plus the indicated
concentrations of 4-chloro-m-cresol (A–D) or caffeine (E–H); the amount of IL-6 released in the supernatant was determined by ELISA. Data
represent the mean ( S.E.) of experiments carried out at least three times in duplicate. Empty boxes, cells from controls (at least four different
individuals; A and E); filled boxes, cells from MHS individuals bearing the V2168M RYR1 mutation (eight different individuals; B and F); crossed
boxes, cells from the CCD individual bearing the I4898T RYR1 mutation (C and G); lined boxes, cells from the CCD individual bearing the R4893W
RYR1 mutation (D and H). dantro, cells incubated with 20 M dantrolene plus 600 M 4-chloro-m-cresol.
FIG. 4. Resting calcium concentration of human myotubes
from control individuals and individuals bearing RYR1 muta-
tions. Average resting myoplasmic [Ca2] of cells from control, MHS
individuals, and CCD individuals bearing the indicated RYR1 muta-
tion. Values are the mean ( S.E.) of the indicated number of analyzed
cells. The [Ca2]i was measured using the fluorescent Ca
2 indicator
Fura-2, in Krebs Ringer containing 1 mM CaCl2. (Student’s t test, **,
p  0.0001).
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resulted in the release of 5.5  0.8 ng/106 cells. Background
release of IL-6 in the absence of added RYR agonist was similar
in myotubes from control and MHS individuals (mean  S.E.;
release was 2.1  0.5 and 2.99  0.2 ng/106 cells, respectively).
Fig. 3 (C, D, G, and H) summarize the results obtained when
experiments were performed on myotubes from the CCD pa-
tients harboring the I4898T and R4893W RYR1 mutations.
The presence of either mutation in the C-terminal region of
RYR1 caused a significant increase in the background levels of
IL-6 released in the absence of an exogenous pharmacological
activator of the RYR: the mean ( S.E.) amount of IL-6 re-
leased was 8.7  0.4 and 14.7  2.4 ng/106 myotubes carrying
the RYR1 I4898T and R4893W mutations, respectively (p 
0.0001, ANOVA; compared with the background release of
myotubes from control individuals). This background release of
IL-6 blunted the stimulatory effect of 4-chloro-m-cresol to myo-
tubes from the CCD patient harboring the I4898T mutation;
the release induced by 600 M 4-chloro-m-cresol was inhibited
by pre-treatment with 20 M dantrolene (Student’s t test p 
0.0012; Fig. 3C). On the other hand, addition of caffeine caused
a significant increase in IL-6 release, compared with back-
ground release (p  0.004; ANOVA, Fig. 3G). 4-chloro-m-cresol
(figure 3 panel D) and caffeine (figure 3 panel H) induced IL-6
release in myotubes from the CCD patient harboring the
R4893W mutation were not significantly different; pre-treat-
ment of these cells with 20 M dantrolene, caused a significant
reduction in IL-6 release by 600 M 4-chloro-m-cresol (Stu-
dent’s t test p  0.007).
[Ca2]i Homeostasis in Cultured Human Myotubes Carrying
RYR1 Mutations—We assessed the intracellular calcium home-
ostasis of myotubes from individuals carrying different muta-
tions in RYR1 by studying: (i) resting myoplasmic free calcium
concentration; (ii) KCl-induced (depolarization) calcium release
and (iii) 4-chloro-m-cresol induced calcium release. All muta-
tions caused a small but significant increase in the [Ca2]i
(Student’s t test, p  0.0001); the difference between the mean
resting [Ca2]i of muscle cells from control and RYR1-mutation
bearing individuals was 13 nM. However no difference was
found when comparing [Ca2]i from muscle cells bearing the
different RYR1 mutations (p  0.937; ANOVA, Fig. 4).
In the next series of experiments we determined whether
cells carrying different RYR1 mutations respond differently to
treatment with RYR1 agonists. Fig. 5 shows a representative
single cell [Ca2]i measurement experiment: addition of the
agonists resulted in an increase in the myoplasmic [Ca2]i,
which varied in extent depending on the mutation present and
agonist concentration used. Fig. 6 shows the changes in fluo-
rescence induced by the addition of different concentrations of
KCl to myotubes from controls, MHS and CCD individuals. In
control cells the EC50 for KCl-induced calcium release was 30
mM KCl, and maximal release was observed at 60 mM KCl,
whereas in cells from MHS individuals harboring the V2168M
mutation the EC50 for KCl-induced calcium release was 10 mM.
In cells from the CCD patient harboring the RYR1 I4898T
mutation the EC50 for KCl-induced calcium release was 40 mM,
whereas cells harboring the R4893W RYR1 mutation were
more sensitive to KCl-induced calcium release (EC50 for KCl
was 10 mM). Cells from both CCD patients, however, released
significantly less calcium compared with cells from control or
MHS individuals.
We next assessed cells from the different patients for their
response to the RYR-specific activator 4-chloro-m-cresol (Fig. 7);
muscle cells from control individuals had an EC50 of 120 M for
4-chloro-m-cresol-induced calcium release, whereas all cells har-
boring RYR1 mutations were more sensitive to the agonist and
had a lower EC50 for 4-chloro-m-cresol-induced calcium release
(the EC50 values were 10 and 50 M for cells from MHS individ-
uals harboring the V2168M mutation and cells from CCD indi-
viduals, respectively). Of interest the cells from the CCD patient
harboring the R4893W mutation released very little calcium
when challenged even with high (up to 600 M) concentrations of
4-chloro-m-cresol. As observed with KCl, cells from patients af-
fected by CCD, irrespective of the mutation released less calcium
than cells from MHS or control individuals.
Finally we compared the calcium released from the intracel-
lular stores of myotubes by 150 mM KCl, 600 M 4-chloro-m-
cresol, or 10 mM caffeine (Fig. 8). Addition of the agonists
caused similar increases in the myoplasmic [Ca2]i of the myo-
tubes obtained from control and MHS individuals; on the other
hand, irrespective of which mutation was present in the C-
FIG. 5. Calcium release stimulated
by 4-chloro-m-cresol and KCl in hu-
man myotubes from control individ-
uals and individuals bearing RYR1-
mutations. B–E, single cell intracellular
Ca2 measurements of Fura-2-loaded hu-
man myotubes. A, phase contrast; B, rest-
ing [Ca2]i before the application of 100
mM KCl and 10 (C), 30 (D), and 40 (E) s
after the application of 100 mM KCl. Myo-
tubes were individually stimulated by ad-
dition of the agonist in Krebs-Ringer
buffer containing 0.5 mM EGTA, 100 M
La3, thus the increase in [Ca2]i repre-
sents only release of calcium from intra-
cellular stores. Experiments were as
described under “Experimental Proce-
dures.” The bottom traces show represent-
ative curves obtained after stimulation of
single cells (arrow) with 4-chloro-m-cresol
(25 M, top left; 600 M, top right) and KCl
(10 mM, bottom left; 100 mM, bottom
right). Solid lines, control; dashed and
dotted lines, MHS; and dotted lines, CCD.
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terminal domain of the RYR1, myotubes from CCD individuals
were always less responsive, because stimulation with KCl,
4-chloro-m-cresol, or caffeine induced significantly smaller
changes in the [Ca2]i.
DISCUSSION
This is the first report in which some of the physiological
properties of myotubes harboring endogenous mutations in the
C-terminal domain of RYR1 obtained from individuals affected
by CCD were investigated. We (i) compared the calcium release
properties of myotubes from patients bearing the different
RYR1 mutations and (ii) investigated whether cultured human
myotubes are capable of releasing IL-6 after activation of the
ryanodine receptor and whether there are differences between
cells from normal individuals and individuals bearing MH and
CCD-linked RYR1 mutations.
During the past years a number of studies have addressed
the role of growth factors and inflammatory cytokines in mus-
cle physiology (31, 47). IL-6 is a member of pro-inflammatory
cytokines, which also include IL-1 and tumor necrosis factor;
these cytokines are also known as endogenous pyrogens, be-
cause they are capable of increasing body temperature and
stimulating the release of acute phase proteins from the liver
(35). Although IL-6 is released by cells of the immune system,
other cell types, including skeletal muscle cells can produce
and release this cytokine (32, 48, 49). Of interest, the plasma
levels of IL-6 have been shown to increase by almost 100-fold
after a marathon race, and a role for changes in the myoplasmic
calcium concentration in IL-6 release from human muscle cells
has been put forward (32, 48). Available data indicate that in
skeletal muscle this cytokine may act as a hormone in the
maintenance of glucose homeostasis during muscle contraction
(32). However, IL-6 must also have an autocrine effect, because
muscle cells express the IL-6 receptor and up-regulation of its
transcript has been demonstrated following muscle injury (50).
The results of the present investigation are relevant to dem-
onstrate an important role of calcium signaling in excitation-
transcription coupling. Our results show that human myotubes
are capable of releasing IL-6 several hours after RYR1 activa-
tion and that the presence of a RYR1 mutation affects the
amount of IL-6 released. RYR1 activation specifically caused
IL-6 release from cultured human myotubes since: (i) IL-6
release was elicited by both 4-chloro-m-cresol and caffeine, two
agonists that activate calcium release via RYR1 (24, 46); (ii)
IL-6 release could be blocked by pre-treatment with dan-
trolene, a substance that specifically closes the calcium chan-
nel, thereby blocking calcium release from the sarcoplasmic
FIG. 6. Calcium release stimulated by KCl in human myotubes. Calcium imaging was performed as described for Fig. 5 and under
“Experimental Procedures”: the curves show the KCl dose-dependent change in calcium, expressed as a change in fluorescence ratio (peak ratio
340/380 nm; resting ratio 340/380 nm). Each point represents the mean (S.E.) of the change in fluorescence of 5–10 measurements. Dose-response
curves were generated using the Origin software.
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reticulum (44). Of interest, in cells from controls and MHS
individuals, the concentration of 4-chloro-m-cresol causing
maximal IL-6 release paralleled its maximal calcium releasing
effect. On the other hand, IL-6 release from myotubes from
CCD patients appears to be more complex. The most intriguing
observation is that myotubes harboring RYR1 mutations in the
C-terminal domain of the RYR exhibited a 4-fold increase in the
background level of IL-6 released compared with cells from
controls or MHS individuals. Such a background IL-6 release
likely attenuates the IL-6-releasing effect of 4-chloro-m-cresol,
because it would be difficult to overstimulate the IL-6-releasing
pathway. The IL-6 release observed in the presence of 4-chloro-
cresol is sensitive to the RYR blocker dantrolene indicating
that it involves RYR activation. Thus, it is plausible that the
background IL-6 release may result, at least in part, from
“unprompted calcium release events” via RYR. The hypothesis
of unprompted release via RYR is consistent with (i) data
obtained in CCD lymphocytes and with (ii) the observation that
calcium release from intracellular stores of myotubes from
CCD patients is decreased in the presence of EGTA in the
extracellular medium, a condition that does not allow the full
recharge of the calcium store (Fig. 8). The latter condition is in
line with previous reports (15, 51) showing that recombinant
RYR1 channels in which Ile-4898 was replaced by either Ala,
Val, or Leu, or carrying a 5-amino acid deletion in the C-
terminal region, failed to close completely for long time periods
even in the presence of mM EGTA. We measured calcium re-
lease in the presence of EGTA to evaluate the release from the
stores to exclude calcium signals generated by influx of calcium
from the extracellular medium. During the determination of
IL-6 release, the presence of extracellular calcium would facil-
itate recharging of calcium stores, enhancing the driving force
of calcium release through mutated RYR via unprompted
events or via RYR agonist activation. For the above reasons, we
believe that the presence of extracellular calcium during the
IL-6 release assay accounts for the apparent miss-correlation
between the effect of 4-chloro-cresol on calcium release (Fig. 8)
and on IL-6 release (Fig. 3). Altogether these results are con-
sistent with the idea that the one or more calcium signals
generated via activation of RYR1 is relevant to the signal
transduction pathway leading to IL-6 release in human myo-
tubes, but we can not exclude the possibility that other signals
might also be involved. In this context it should be kept in mind
that calcium-independent mechanisms have also been impli-
cated in IL-6 release (32, 52, 53).
In many cases cytokine production is regulated by the intra-
cellular calcium concentration, via the phosphatase calcineurin
and the nuclear factors of activated T cells (NF-AT)-signal
FIG. 7. Calcium release stimulated by 4-chloro-m-cresol in human myotubes. Curves show the 4-chloro-m-cresol dose-dependent change
in calcium, expressed as change in fluorescence ratio (peak ratio 340/380 nm; resting ratio 340/380 nm). Each point represents the mean (S.E.)
of the change in fluorescence of 5–10 measurements. Dose-response curves were generated using the Origin software. Conditions as described for
Fig. 6.
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transduction pathway (30). The results of the present investi-
gation show that activation of the RYR leads to a calcineurin-
dependent IL-6 release, because pre-treatment with cyclospo-
rine blocked release of this cytokine from human myotubes. It
will be interesting to study whether release of other muscle-
derived cytokines such as IL-4, IL-15, and IL-13 whose tran-
scription is regulated by the NF-AT pathway can also be elic-
ited by RYR activation. The release of cytokines via activation
of RYR1 also has important implications in MH. This condition
is characterized by hypermetabolism and a rapid increase in
body temperature following the administration of trigger
agents (7–9). Point mutations in RYR1 not only affect the
amount of calcium released from the sarcoplasmic reticulum
but also, in view of the present findings, the amount of IL-6
that can potentially be released. Because muscle mass consti-
tutes more than 40% of total body weight, part of the down-
stream effects of mutations in RYR1 may include an increase in
the circulating levels of IL-6, which may result in fever, muscle
wasting, and fiber type switching (via Myf5 gene expression)
(54). From a histological point of view MH does not induce
major changes in muscle fiber appearance, whereas CCD is
associated with fiber atrophy/hypotrophy (1–6). Thus alter-
ations of calcium homeostasis caused by RYR-linked mutations
in CCD patients, could potentially influence the signaling path-
ways responsible for the trophic status of muscle fibers and
account for the different phenotypes (MH versus CCD), which
are associated with mutations of the same molecule. Cytokine
release experiments on a larger number of cells from patients
affected by CCD may help clarify the clinical relevance of this
novel observation.
During the past decade a number of studies have appeared
concerning the functional impact of mutations in the RYR1
gene associated with CCD and/or the MHS phenotype (9–11).
Most MH-linked mutations are clustered within two domains
of the large hydrophilic region of the RYR protomer and cause
a shift in the dose-response curve to agonists such as caffeine,
4-chloro-m-cresol, and halothane (9–11, 22–24). As far as the
MH-linked RYR1 V2168M mutation is concerned, the results of
the present investigation are consistent with our previous stud-
ies using immortalized lymphoblastoid cells of the same geno-
type (46) and those of Yang et al. (25) using dyspedic mouse
myotubes transduced with wild type or mutated RYR1 cDNA.
The presence of the mutation resulted in a shift in the EC50 of
calcium release stimulated by 4-chloro-m-cresol from 130 to
28 M, in wild type and mutation carrying myotubes, respec-
tively. Similarly, the dose-response curve for KCl-induced cal-
cium release was shifted in myotubes from MHS individuals
carrying the V2168M RYR1 mutation. These results confirm
those of Yang et al. (25) and Gallant et al. (55) except that
under our experimental conditions the EC50 for KCl-induced
calcium release 2-fold lower; the differences most likely re-
flect differences in the experimental approaches and the use of
different calcium indicators.
CCD-linked RYR1 mutations in the C-terminal transmem-
brane domain have been shown to cause reduced calcium re-
lease following RYR activation (17, 20). This observation has
been explained by the “leaky channel” hypothesis, which states
that the presence of C-terminal CCD-linked RYR1 mutations
result in a reduction of the intracellular calcium stores, which
in turn cause muscle weakness, because the contractile force in
normal excitation-contraction coupling is proportional to acti-
vating Ca2. For some mutations, however, a second hypothe-
sis has been put forward: the presence of C-terminal RYR1
mutations reduces voltage-dependent calcium release even in
the absence of sarcoplasmic reticulum calcium store depletion,
i.e. there is excitation-contraction uncoupling (26, 27). The
FIG. 8. Increase in [Ca2]i induced by KCl, 4 chloro-m-cresol,
and caffeine in human myotubes from control, MHS, and CCD
individuals. Change in fluorescence ratio (peak ratio 340/380 nm;
resting ratio 340/380 nm) induced by 150 mM KCl, 600 M 4-chloro-m-
cresol, and 10 mM caffeine in Krebs-Ringer containing 0.5 mM EGTA
and 100 M La3. Results are the mean (S.E.) of n (6–34) independent
measurements.
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results of the present investigation support the overall view
that mutations in the C-terminal domain of RYR1 reduce the
amount of calcium that is released via the RYR calcium chan-
nel, whereby cells expressing mutant C-terminal channels
have an altered excitation-contraction coupling. As to the dif-
ferences in agonist-induced calcium release between our re-
sults and those of Avila et al. (27), they probably reflect the
different experimental models used; i.e. dyspedic mouse myo-
tubes reconstituted with recombinant homozygous mutated
rabbit RYR1 on a homogeneous genetic background, versus
expression of the endogenous heterozygous mutation in cul-
tured human myotubes on the patient’s individual genetic
background.
As far as the resting myoplasmic calcium concentration is
concerned, cells carrying any RYR1 mutation had a small but
significantly higher resting calcium concentration, supporting
previous observations that the presence of RYR1-linked muta-
tions does not grossly alter the resting calcium concentration of
cells expressing the native endogenous mutation (22, 27). This
is expected, because resting calcium is the net balance between
efflux from the sarcoplasmic reticulum via the RYR, re-uptake
into the sarcoplasmic reticulum via the sarcoplasmic reticulum
Ca2-ATPase, and the activity of other calcium extrusion path-
ways. A high myoplasmic calcium concentration would be det-
rimental to the cells, possibly activating calcium-dependent
proteases and eventually leading to cell death.
In conclusion our data show that skeletal muscle cells re-
spond to RYR activation by releasing IL-6, and that the pres-
ence of RYR1 mutations not only affects calcium homeostasis
but, indirectly, also the amount of cytokine released. Our data
also show that myotubes from patients affected by CCD release
significantly more IL-6 compared with cells from control and
MHS individuals and point toward a complex and heterogene-
ous pathogenetic pathway leading to the myopathy in CCD
patients with different mutations.
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